Get the Stockscreener App
1.05
0.00%
0.00
Pre-market:
1.09
0.04
+3.81%
Adc Therapeutics Sa stock is traded at $1.05, with a volume of 1.85M.
It is up +0.00% in the last 24 hours and down -67.69% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
See More
Previous Close:
$1.05
Open:
$1.08
24h Volume:
1.85M
Relative Volume:
1.16
Market Cap:
$133.55M
Revenue:
$79.18M
Net Income/Loss:
$-136.99M
P/E Ratio:
-0.9955
EPS:
-1.0547
Net Cash Flow:
$-120.11M
1W Performance:
+7.39%
1M Performance:
-67.69%
6M Performance:
-75.06%
1Y Performance:
-70.67%
1-Day Range:
$1.02
$1.096
1-Week Range:
$0.97
$1.22
52-Week Range:
$0.7796
$4.98
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.05 | 133.55M | 79.18M | -136.99M | -120.11M | -1.0547 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
Bronstein, Gewirtz & Grossman, LLC Encourages ADC Therapeutics SA (ADCT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-06-14 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ADC Therapeutics SA (ADCT) and Encourages Investors to Learn More About the Investigation | NYSE:ADCT | Press Release - Stockhouse
Are medical stocks lagging ADC Therapeutics (ADCT) this year? - MSN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ADC Therapeutics SA (ADCT) And Encourages Stockholders to Reach Out - ACCESS Newswire
ADC Therapeutics SA (ADCT) reports Q1 loss, beats revenue estimates - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating ADC Therapeutics SA (ADCT) And Encourages Stockholders to Connect - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ADC Therapeutics SA (ADCT) Investigation: Bronstein, Gewirtz & Gr - The National Law Review
ADC Therapeutics falls on confirmatory trial data for lymphoma therapy - MSN
ADCT Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCLSlideshow - Seeking Alpha
ADC Therapeutics Shares Fall After HC Wainwright Downgrade - marketscreener.com
This ADC Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Monday - Benzinga
ADC Therapeutics (ADCT) Is Down 69.7% After Mixed LOTIS-5 ZYNLONTA DataHas The Bull Case Changed? - Yahoo Finance
ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursda - Benzinga
ADC Therapeutics: 'Sell' LOTIS-5 Underwhelms And Possible Change In Strategy (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics SA (ADCT) Stock Price, Quote, News & History - Benzinga
Why Is ADC Therapeutics Stock Falling On Friday?ADC Therapeutics (NYSE:ADCT) - Benzinga
Why Is ADC Therapeutics Stock Falling Thursday? - Sahm
ADC Therapeutics’ Zynlonta Clears Phase III PFS Bar But Safety Concerns Cloud FDA Path - Citeline News & Insights
ADCT stock plunges on safety concerns despite positive lymphoma data - MSN
ADCT Downgraded by RBC Capital -- Price Target Lowered to $2.00 - GuruFocus
Zynlonta Lotis position in DLBCL strains ADC shares - BioWorld News
ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data - Yahoo Finance
ADC Therapeutics plunges after patient deaths in blood cancer drug trial - Reuters
ADC Thera falls on trial data for lymphoma drug (ADCT:NYSE) - Seeking Alpha
RBC Downgrades ADC Therapeutics to Sector Perform From Outperform, Cuts Price Target to $2 From $6, Keeps Speculative Risk - marketscreener.com
An ADC specialist sinks on safety concerns for blood cancer drug - Yahoo Finance
RBC Capital cuts ADC Therapeutics stock rating on trial results By Investing.com - Investing.com UK
ADC Therapeutics stock plunges on trial safety concerns By Investing.com - Investing.com Australia
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirma - GuruFocus
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma - BioSpace
Has ADC Therapeutics' ZYNLONTA Delivered on its Phase 3 Promise - Kavout
ADC Therapeutics stock plunges on trial safety concerns - Investing.com
ADC Therapeutics reports positive phase 3 trial results By Investing.com - Investing.com India
ADC Therapeutics reports positive phase 3 trial results - Investing.com
ADCT: LOTIS-5 met its PFS endpoint, with durable CRs but higher Grade 5 events in elderly patients - TradingView
ADCT: LOTIS-5 met its primary PFS endpoint, with Lonca-R showing higher CR rates than R-GemOx - TradingView
ADC Therapeutics' Drug Regimen to Treat B-Cell Lymphoma Meets Primary Endpoint of Progression-Free Survival in Phase 3 Trial - marketscreener.com
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
ADC Therapeutics (NYSE: ADCT) director gets 45K RSUs, 12.6K shares withheld - Stock Titan
ADC Therapeutics (ADCT) director receives RSU award and shares withheld for taxes - Stock Titan
ADC Therapeutics (ADCT) director logs RSU grant and tax withholding on Form 4 - Stock Titan
ADC Therapeutics (ADCT) director granted 45K RSUs, 2.6K shares withheld - Stock Titan
ADC Therapeutics (ADCT) director receives 45,000 RSUs and 2,156-share tax withholding - Stock Titan
ADC Therapeutics (ADCT) director RSU grant and 12,600-share tax withholding - Stock Titan
ADC Therapeutics (NYSE: ADCT) director gets RSU grant and tax withholding - Stock Titan
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):